A. Dufresne

发表

SELNET Clinical practice guidelines for bone sarcoma.

R. Maki, A. D. Dei Tos, J. Martín-Broto, 2022, Critical reviews in oncology/hematology.

Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials

O. Mir, A. Le Cesne, I. Ray-Coquard, 2022, ESMO open.

Histiocytosis X mimicking the follicular occlusion syndrome: response to local therapy.

L. King, K. E. Salhany, A. Dufresne, 1987, Journal of the American Academy of Dermatology.

Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors

F. Tirode, A. Le Cesne, H. Vanacker, 2023, ESMO open.

LBBB Induced by Quetiapine Overdose: A Case Report and Literature Review.

M. Khalid, D. Sapkota, Ahmed Bakhit, 2017, American journal of therapeutics.

Epithelioid hemangio-endothelioma (EHE) in NETSARC: The nationwide series of 267 patients over 12 years.

F. Bertucci, M. Toulmonde, A. Italiano, 2023, European journal of cancer.

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer

J. Blay, V. Grégoire, B. Fervers, 2021, ESMO open.

Sclerosing Epithelioid Fibrosarcoma (SEF) versus Low Grade Fibromyxoid Sarcoma (LGFMS): presentation and outcome in the nationwide NETSARC+ series of 330 patients over 13 years

M. Toulmonde, F. Ducimetière, C. Chemin-Airiau, 2023, European Journal of Cancer.

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

C. Tournigand, M. Espié, B. Weber, 2019, The Lancet.